Nxera Pharma Co., Ltd.
SOLTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $45,657 | $8,450,000 | $6,644,000 | $6,852,000 |
| % Growth | -99.5% | 27.2% | -3% | – |
| Cost of Goods Sold | $18,069 | $1,858,000 | $1,615,000 | $2,127,000 |
| Gross Profit | $27,588 | $6,592,000 | $5,029,000 | $4,725,000 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| R&D Expenses | $25,188 | $3,666,000 | $3,808,000 | $3,299,000 |
| G&A Expenses | $0 | $0 | $0 | -$1,031,000 |
| SG&A Expenses | $25,985 | $3,865,000 | $3,701,000 | $1,207,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2,238,000 |
| Other Operating Expenses | $0 | $287,000 | -$287,000 | $3,985,000 |
| Operating Expenses | $51,173 | $7,818,000 | $7,222,000 | $8,491,000 |
| Operating Income | -$23,586 | -$1,226,000 | -$2,193,000 | -$3,766,000 |
| % Margin | -51.7% | -14.5% | -33% | -55% |
| Other Income/Exp. Net | $2,521 | -$340,000 | $37,000 | $1,397,000 |
| Pre-Tax Income | -$21,064 | -$1,566,000 | -$2,156,000 | -$2,369,000 |
| Tax Expense | -$9,761 | $811,000 | $1,396,000 | $1,034,000 |
| Net Income | -$11,303 | -$2,377,000 | -$760,000 | -$1,335,000 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS | -0.12 | -26.35 | -8.45 | -14.85 |
| % Growth | 99.5% | -211.8% | 43.1% | – |
| EPS Diluted | -0.12 | -26.35 | -8.45 | -14.86 |
| Weighted Avg Shares Out | 90,495 | 90,209 | 89,901 | 89,860 |
| Weighted Avg Shares Out Dil | 90,495 | 90,209 | 89,901 | 89,902 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,616 | $1,769 | $37,000 | $156,000 |
| Interest Expense | $1,379 | $1,003,000 | $0 | $0 |
| Depreciation & Amortization | $7,477 | $1,095,000 | $1,082,000 | $1,003,000 |
| EBITDA | -$12,209 | $532,000 | -$1,111,000 | -$2,775,000 |
| % Margin | -26.7% | 6.3% | -16.7% | -40.5% |